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a b s t r a c t
Besiﬂoxacin (BSF) is a synthetic chiral ﬂuoroquinolone developed for the topical treatment of ophthalmic
infections. The present study reports the development and validation of a microbiological assay, applying
the cylinder-plate method, for determination of BSF in ophthalmic suspension. To assess this methodol-
ogy, the development and validation of the method was performed for the quantiﬁcation of BSF by high
performance liquid chromatography (HPLC). The HPLC method showed speciﬁcity, linearity in the range
of 20–80 mg mL1 (r¼0.9998), precision, accuracy and robustness. The microbiological method is based
on the inhibitory effect of BSF upon the strain of Staphylococcus epidermidis ATCC 12228 used as a
test microorganism. The bioassay validation method yielded excellent results and included linearity,
precision, accuracy, robustness and selectivity. The assay results were treated statistically by analysis of
variance (ANOVA) and were found to be linear (r¼0.9974) in the range of 0.5–2.0 mg mL1, precise (inter-
assay: RSD¼0.84), accurate (101.4%), speciﬁc and robust. The bioassay and the previously validated high
performance liquid chromatographic (HPLC) method were compared using Student´s t test, which
indicated that there was no statistically signiﬁcant difference between these two methods. These results
conﬁrm that the proposed microbiological method can be used as routine analysis for the quantitative
determination of BSF in an ophthalmic suspension. A preliminary stability study during the HPLC
validation was performed and demonstrated that BSF is unstable under UV conditions. The photo-
degradation kinetics of BSF in water showed a ﬁrst-order reaction for the drug product (ophthalmic
suspension) and a second-order reaction for the reference standard (RS) under UVA light. UVA degraded
samples of BSF were also studied in order to determine the preliminary in vitro cytotoxicity against
mononuclear cells. The results indicated that BSF does not alter the cell membrane and has been
considered non-toxic to human mononuclear cells in the experimental conditions tested.
& 2013 Elsevier B.V. All rights reserved.
1. Introduction
Increased research and development of synthetic drugs in the
last decades are reﬂected in the large number of drugs available.
Fluoroquinolones are a group of chemotherapeutic compounds of
synthetic origin, characterized by a pharmacological and thera-
peutic effect that is increasingly promising at each generation
[1,2]. BSF (Fig. 1) is a synthetic chiral ﬂuoroquinolone, marketed in
an enantiomeric pure form and developed for the topical treat-
ment of ophthalmic infections. It was approved by FDA in May
2009 and it is the only ophthalmic ﬂuoroquinolone that has not
been studied primarily for systemic use [3,4].
It became part of the therapeutic arsenal in Brazil in 2011, but it
has been sold in the USA by Bausch & Lomb under the tradename
of Besivances ophthalmic suspension 0.6%, formulated with
DuraSites technology that allows the active ingredient to remain
longer on the surface of the eye [5].
The literature has reported the determination of BSF in biolo-
gical ﬂuids [6–10], but no published scientiﬁc papers refer to the
determination of BSF in raw material and its pharmaceutical form,
ophthalmic suspension.
The importance of developing and validating analytical meth-
ods for this drug is justiﬁed by its therapeutic potential, the
absence of such speciﬁc information in the literature, as well as
the knowledge that the poor quality of anti-infective products
is related to the emergence of resistant strains, resulting from
the administration of subtherapeutic doses. Therefore this study is
relevant for therapeutic application in the international market.
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In order to overcome this lack of information about validated
methodologies, the present study reports the development and
validation of two analytical methods to determine BSF in ophthal-
mic suspension: HPLC and microbiological assay by agar diffusion
using the cylinder-plate methods. The HPLC method developed
and validated was chosen as a comparison method for the
determination of BSF in ophthalmic suspension.
A preliminary stability study was performed during HPLC
validation and shows that BSF is unstable under light conditions.
This led to the study of the degradation kinetics of BSF under
UVA light. The UVA degraded samples of BSF were also studied in
order to determine the preliminary in vitro cytotoxicity against
mononuclear cells.
2. Materials and methods
2.1. Chemicals
Besiﬂoxacin hydrochloride RS (99.6%) was acquired from
Sequoia Research Products. Besivances (Bausch & Lomb Incorpo-
rated) besiﬂoxacin ophthalmic suspension 0.6% was obtained by
the courtesy of Bausch & Lomb Incorporated and purchased in the
local market.
The excipient ingredients contained in suspension form (poly-
carbophil, mannitol, polaxamer 407, sodium chloride, edetate
disodium dehydrate, sodium hydroxide and water for injection)
were of pharmaceutical grade and were obtained from different
suppliers. All chemicals used were of analytical grade and all
solvents were of HPLC grade. Acetonitrile was purchased from
Tedias (Fairﬁeld, USA). Phosphoric acid and triethylamine were
purchased from Merck (Darmstadt, Germany).
Sodium chloride, sodium hydroxide, Grove–Randall's 1 culture
medium and Grove–Randall's 11 culture medium were obtained
from Mercks (Darmstadt, Germany). Puriﬁed water was obtained
using a Milli-Q Pluss (Millipore, Bedford, USA).
2.2. Apparatus
A photostability UV chamber (1.0 m0.17 m0.17 m) was
used with mirrors in its interior, equipped with a UVA lamp (Light
Expresss, 352 nm, 30 W) and UV cuvettes (Ultra Vettes, São
Paulo, Brazil) for photodegradation studies.
A dry air oven (Biomatics, Porto Alegre, Brazil) was utilized for
thermal stability studies.
An electronic caliper (Mitutoyos, Tokyo, Japan) was used to
measure the diameters of growth zone inhibition.
The HPLC system consisted of an Agilents liquid chromatograph
(Santa Clara, CA, USA) with a model Q 1311A quaternary pump, ALS-
G1329 auto sampler, TCC-G1316A column oven, G1315B photodiode-
array detector and ChemStationsmanager system software, using an
Agilents Eclipse Plus C18 column (150mm4.6 mm i.d., 5 mm, Santa
Clara, CA, USA). For the cytotoxicity assay a Ficoll-Paque gradient
centrifuge (Sigmas), Hank's medium, centrifuge, hemocytometer
ABX-Micros 60s, commercial kit (Doless reagents, Goiânia, Brazil)
and an Envision plate reader (Perkin Elmers) were used.
2.3. BSF RS solutions
An accurately weighed amount of BSF RS equivalent to 10.0 mg
of BSF base was transferred quantitatively to a 200 mL volumetric
ﬂask and dissolved in water to obtain a ﬁnal concentration of
50.0 mg mL1. Aliquots of this solution were diluted in water to
achieve concentrations of 0.5, 1.0 and 2.0 mg mL1 (S1, S2 and S3,
respectively). These solutions were kept protected from the light
and used in a microbiological assay. In the HPLC method (APPLI-
CATION), the concentration of 500.0 mg mL1 of BSF dissolved in
water was used. Aliquots of this solution were removed and
diluted in mobile phase for analysis on HPLC.
A stock solution of 500.0 mg mL1 was also used for stability
tests and kinetics studies.
A solution of 2.0 mg mL1 was used for the cytotoxicity assay.
2.4. Sample solution preparation
An aliquot equivalent to 5 mg of BSF base was removed from
the sample bottle and transferred to a 100 mL volumetric ﬂask
with the aid of 50 mL of water, kept in an ultrasonic bath for
25 min, and the volume was completed with the same solvent.
Aliquots of this solution were further diluted in water to achieve
concentrations of 0.5, 1.0 and 2.0 mg mL1 (T1, T2 and T3, respec-
tively). These solutions were protected from light and used in the
bioassay.
To perform the analysis by HPLC method, a concentration of
500.0 mg mL1 of BSF sample/drug product dissolved in water was
used. From this solution aliquots were removed and diluted in a
mobile phase for HPLC analysis.
The solution of 500.0 mg mL1 was also used for stability tests
and kinetics studies.
A solution of 2.0 mg mL1 was used for a cytotoxicity assay.
2.5. HPLC method
This method was developed and validated in order to monitor
and compare the results obtained with the microbiological assay
for determination of BSF in an ophthalmic suspension.
The BSF concentration analysis was performed on an Agilents
liquid chromatograph with a C18 column (Agilents Eclipse Plus
5 mm, 150 mm4.6 mm). The mobile phase comprised a mixture
of 0.5% triethylamine solution (pH adjusted to 3.0 with 10%
phosphoric acid) and acetonitrile (74:26, v/v) at a ﬂow rate of
1.0 mL min1. The injection volume was 20 mL for both reference
substance and drug product solutions. The temperature was set at
25 1C in the column oven. BSF was determined by UV detection at
295 nm using a photodiode-array.
2.6. Microbiological assay
2.6.1. Microorganism and inoculum standardization
The strain of Staphylococcus epidermidis ATCC 12228 obtained
from INCQS (Rio de Janeiro, Brazil) was cultivated after reconstitu-
tion and maintained in medium number 1. The microorganism
was standardized according to the procedure described in the
Brazilian [11] and United States [12] Pharmacopeia. Prior to use,
the microorganism was transferred and inoculated in a test tube
containing the same medium, which was maintained in a dry air
oven for 24 h at 37772 1C. Using a spectrophotometer (Analy-
sers, São Paulo, Brazil) with wavelength set at 580 nm and a
10 mm absorption cell, the broth containing the microorganism
was diluted in 0.9% NaCl sterile solution to give a suspension with
Fig. 1. Chemical structure of BSF.
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25772% turbidity (transmittance) with the same sterile solution
as the blank. From this standardized suspension, aliquots of 2.0 mL
were added to each 100 mL of Grove–Randall's 11 culture medium,
kept in a water bath at 48 1C, and used as an inoculated layer in
the plate.
2.6.2. Agar diffusion bioassay
The bioassay described followed the 33 parallel line assay
design according to the Brazilian and European Pharmacopoeia
[11,13].
The base layer agar was composed of 20 mL Grove–Randall's 11
culture medium that was poured into a 10020 mm Petri dish. After
layer solidiﬁcation, portions of 5 mL of inoculated Grove–Randall's 11
medium were poured onto the base layer. In each plate, six stainless
steel cylinders of uniform size (8610 mm) were placed on the
surface of the inoculated medium. Three alternated cylinders were
ﬁlled with 200 μL of the reference solutions (S1, S2, and S3), and the
other three cylinders were ﬁlled with the concentrations of the
sample solutions (T1, T2, and T3). Six plates were used for each assay.
The plates were incubated at 35771 1C aerobically for 18 h. The
growth inhibition zone diameters (mm) were carefully measured
with a digital caliper (Mitutoyos, Tokyo, Japan). All experiments
were performed in a biological safety cabinet and the infected
material was decontaminated before being discarded.
2.6.3. Calculations
The BSF potency was statistically calculated by a parallel-line
model for the 33 assay design [14]. Analysis of variance
(ANOVA) was used for the statistical validation of the bioassays,
evaluating regression, parallelism and linearity for each assay.
2.7. Method validation (HPLC method and microbiological assay)
(ICH Q2, USP)
The methodologies were validated according to USP 34 [12]
and the International Conference on Harmonization (ICH) guide-
lines [15] by determining the speciﬁcity, linearity, precision,
accuracy, robustness, and stability of the reference standard and
sample solutions.
2.7.1. Speciﬁcity
HPLC method – Forced degradation studies were performed for
BSF RS and the drug product (500 mg mL1) to show the speciﬁcity
of the method. The interference of excipients was also evaluated
and all the solutions used in the assay were protected from the
light. Blank solutions were used during the analysis. Fresh BSF
RS and drug product solutions were prepared and compared to
quantitative results of the forced degradation studies. The stress
conditions were the following:
Acid hydrolysis: Sample solutions were prepared and main-
tained in 1.0 M HCl for 1 h and stored at room temperature. After
this time, aliquots of these solutions (500 μg mL1) were removed,
neutralized with 1.0 M NaOH and diluted in water to achieve a
theoretical concentration of 50 μg mL1.
Basic hydrolysis: Sample solutions were prepared and main-
tained in 1.0 M NaOH for 1 h and stored at room temperature.
After this time, aliquots of these solutions (500 μg mL1) were
removed, neutralized with 1.0 M HCl and diluted in water to
achieve a theoretical concentration of 50 μg mL1.
Oxidative degradation: Sample solutions were prepared in a
30% H2O2 solution and stored at room temperature for 1 h. After
this time, aliquots of these solutions (500 μg mL1) were removed
and diluted in water to achieve a theoretical concentration of
50 μg mL1.
Thermal degradation: Aqueous sample solutions were main-
tained at 60 1C in a dry air oven for 24 h. After this time, aliquots of
these solutions (500 μg mL1) were removed and diluted in water
to achieve a theoretical concentration of 50 μg mL1.
Photodegradation: Each solution was prepared in water and
exposed to UVA radiation (352 nm) and UVC radiation (254 nm)
for 1 h. The stress degradation study was performed by exposing
the solutions in quartz cells in the photodegradation chamber.
Subsequently, these solutions were diluted in a mobile phase to
achieve a concentration of 50 μg mL1. Control samples were
protected from light with aluminum foil and were also placed in
the light chamber and exposed concurrently
Microbiological assay – Speciﬁcity was studied by analyzing the
sample in the presence of the excipients from the formulation
(placebo) and degradation products. The ability to determine BSF
RS in the presence of excipients and/or degradation products was
evaluated by comparing the results obtained from the placebo
suspension and degraded samples analyzed by bioassay and the
HPLC method. In order to ﬁnd out whether some components
of the pharmaceutical form could interfere with the assay, the
sample solutions were assayed and compared to freshly prepared
BSF RS solutions at the same theoretical concentrations.
The stressed condition and excipients solutions were prepared
as below:
Photodegradation: Aqueous drug product solutions (500 μg mL1)
were exposed to UVA radiation (352 nm) for 120 min. A stress
degradation study was conducted by exposing the solution in quartz
cells in the photodegradation chamber. Subsequently, these solutions
were removed and diluted in water to achieve the theoretical
concentrations of 0.5, 1.0 and 2.0 μg mL1. Samples protected from
light with aluminum foil were also exposed in the light chamber and
used as control samples.
Excipients: The amount of formulation excipients contained in
an ophthalmic suspension of besiﬂoxacin was accurately weighed
and dissolved in water.
2.7.2. Linearity
HPLC method – Three calibration curves were prepared with six
concentrations (20.0, 30.0, 40.0, 50.0, 60.0, 70.0 and 80.0 mg mL1)
of BSF RS. For each concentration solutions were prepared and
injected in triplicate. The peak areas of the chromatograms were
plotted against the respective concentration of the drug to obtain
the analytical curves. The regression line was calculated by using
the least squares method and the curves were validated though
analysis of variance.
Microbiological assay – In order to assess the validity of the
assay, three doses of the reference substance were used in six
independent assays. Linearity was evaluated by linear regression
and deviation analysis, which was calculated by the least-squares
method.
2.7.3. Precision
HPLC method – Precision was determined using the parameters
of repeatability (intra-day) and intermediate precision (inter-day),
analyzing six BSF sample solutions prepared at 50 μg mL1 in
triplicate on three different days. The results were expressed as
relative standard deviation (RSD) of the analytical measurements.
Microbiological assay – The precision of the method was
determined by repeatability and intermediate precision and was
expressed as relative standard deviation (RSD). Repeatability was
examined by assaying three samples of BSF on the same day
(intra-day) and under the same experimental conditions that were
compared against the BSF reference standard. The intermediate
precision of the method was determined on 3 days (inter-day).
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2.7.4. Accuracy
HPLC method – Accuracy was calculated as a percentage by adding
known amounts of BSF RS to sample solutions (40 μg mL1) to yield
ﬁnal concentrations of 50.0, 60.0 and 70.0 μg mL1, corresponding to
25%, 50% and 75% of the analytical concentrations.
Microbiological assay – To determine the accuracy of the
proposed method, the test was performed over three concentra-
tion levels adding 10% of BSF RS to each concentration of the
samples (0.55, 1.1 and 2.2 μg mL1).
Accurate aliquots of 0.10, 0.20, and 0.40 mL of the reference
standard solution (5.0 μgmL1) were transferred into 10 mL volu-
metric ﬂasks together with aliquots of 0.10, 0.20 and 0.40 mL of
sample solutions (50 μgmL1) and diluted with water to ﬁnal
concentrations of 0.55, 1.1 and 2.2 μgmL1, respectively (correspond-
ing to 110.0% of the nominal concentrations). The cylinders were ﬁlled
with the solutions described above and recovery rates of the added
BSF RS were calculated.
2.7.5. Robustness
HPLC method – The factors investigated in the robustness evalua-
tion were pH of the aqueous phase (3.070.1), percentage of
acetonitrile (26%71), ﬂow (1.0 mL min170.1) and percentage of
triethylamine (0.5%70.1). The results obtained under these condi-
tions were compared with the original conditions.
Microbiological assay – Determined by analyzing the sample
solution under 70.2% variation in the inoculum concentration.
2.8. BSF photodegradation kinetics
Aqueous sample solutions (500 μg mL1) were exposed to UVA
radiation (352 nm) according to the photodegradation studies
described in Section 2.7.1. At pre-established times (60, 120, 180,
240 and 300 min), 1.0 mL aliquots of the solution were withdrawn
and diluted in water to achieve the concentration of 50 μg mL1.
Aliquots of this solution were diluted in water to achieve concen-
trations of 0.5, 1.0 and 2.0 mg mL1 for the bioassay according to
Sections 2.5–2.7.
2.8.1. Kinetic calculation
The reaction order for the kinetics of BSF degradation was
determined representing the residual drug concentration versus
time (zero order reaction), log concentration versus time (ﬁrst
order reaction) and the inverse of a function of concentration
versus time (second order). Linear regression coefﬁcients (r) were
obtained, and the coefﬁcient closer to unity indicates the order of
reaction. Kinetic parameters such as apparent order degradation
rate constant (k) and t90 (time at which 90% of the concentration of
the drug is unchanged) were obtained.
2.9. Cytotoxicity assay
Cytotoxicity or cell death by necrosis can be determined by
membrane integrity. The intracellular enzyme lactate dehydrogenase
(LDH) is rapidly released into the medium when the cell membrane
is damaged. A commercial kit (DOLES Reagentes, Goiânia, Brazil) was
used to determine LDH release.
Human mononuclear cells of ﬁve healthy donors were sepa-
rated from the peripheral blood. Heparinized venous blood was
diluted 1:1 (v/v) using Hank's balanced salt solution. The mono-
nuclear cells were isolated by centrifugation on a Ficoll-Paques
gradient centrifuge and washed twice in Hank´s solution. Viable
cells were counted in a Neubauer chamber. The mononuclear cells
were washed and suspended in Hank's solution to a concentration
of 107 cells for 1.0 mL.
Pipetting the reagents into a 96-well plate was done in the
following order: ferric alum, substrate and sample solution. The
sample solutions were composed of solutions containing BSF SR
and drug production (with and without degradation under UVA
light). The photodegraded solutions were prepared by exposing
the aqueous solution besiﬂoxacin (2.0 mg mL1) to UVA radiation
during 5 h. After the exposure period, the solution was diluted
with Hank's to a ﬁnal concentration of 10, 100 and 200 μg mL1, in
triplicate. After the samples were added, the plates were main-
tained at 37 1C. Simultaneously, a blank test (baseline) was
performed, in triplicate, with ferric alum and substrate. A positive
control test was also carried out with Triton X-100 (100% cell
death). A blank solution was also made with Hank's solution and
water. Thereafter, an NAD solution was added to each well-plate
and after the time indicated by the kit, the stabilizing solution was
pipetted. After this procedure, ultraviolet absorbance was mea-
sured at 492 nm using an Envision plate reader (Perkin Elmer). The
blank measurement was subtracted from the measurements
obtained for each sample.
2.10. Comparison of the methods
All results in this study were compared with those obtained by
the validated high-performance liquid chromatography (HPLC)
method that was previously described.
3. Results and discussion
3.1. HPLC method
This method was developed and validated in order to monitor
and compare the results obtained with the microbiological assay
for determination of BSF in an ophthalmic suspension. For this
reason, the results will be shown brieﬂy.
The chromatographic conditions were adjusted in order to
provide a good performance of the assay. During method optimiza-
tion, different columns, organic solvents and the aqueous phase were
tested. After testing various combinations of the mobile phase, the
best condition with a retention time of 4.9 min for BSF was obtained
using an Agilent C-18 column (150 mm4.6 mm i.d., particle size
5 mm) maintained at room temperature (25 1C) and the mobile phase
was composed of water with 0.5% triethylamine adjusted to pH
3.0 with phosphoric acid and acetonitrile (74:26, v/v). The addition of
triethylamine improved peak symmetry.
3.2. Bioassay method
Determining antimicrobial potency is important for controlling
the quality of pharmaceutical preparations, and it is necessary to
develop economic and practical procedures that can be validated
and applied to the determination of these drugs [16]. The potency
of antibiotics is generally determined by comparing the dose
which inhibits the growth of a susceptible microorganism with
the dose of preparation of the reference antibiotic that produces
similar inhibition under the same working conditions. A reduction
in microbial activity can reveal changes not demonstrable by
chemical methods [12].
The quantiﬁcation of antimicrobial agents by chemical methods,
such as HPLC and UV spectrophotometry, although accurate, does not
provide a true indication of biological activity. The test microbiolo-
gical agar diffusion-plate cylinder allows drug potency to be quanti-
ﬁed by measuring the area of microorganism growth inhibition,
caused by the diffusion of the drug through the agar [16].
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No ofﬁcial microbiological cylinder-plate assays are described in
the ofﬁcial codes to determine BSF in pharmaceutical formulations,
which demonstrates the relevance of the work developed here.
In this work we chose to use a 33 design in which three
concentration levels of the sample and reference solutions were
tested (Fig. 2), maintaining a geometric progression of the values
used, following the procedure described in the Brazilian (2010)
and European Pharmacopoeia (2005). It is possible to directly
relate the diameter of the zone of inhibition as a function of the
logarithm of the dose used. It is assumed that the response curve
(reference and sample) should display the same inclination [14].
The experimental conditions were adjusted to accurately
determine the assay performance. Some parameters (Table 1)
were tested earlier to establish the ﬁnal conditions described in
Table 2.
All assays were performed in a laminar air ﬂow cabinet, and the
infected material was decontaminated before being discarded.
During microorganism handling, all safety procedures (use of
mask, gloves and goggles) were followed.
3.3. Method validation (HPLC and bioassay methods)
3.3.1. Speciﬁcity
HPLC method – The speciﬁcity analysis revealed that the HPLC
method did not show any interference from the formulation exci-
pients, since there were no other peaks eluting at the same time as
BSF. Photodiode array detection also supported the speciﬁcity of the
method and provided evidence of peak purity for BSF. The BSF drug
product solutions were submitted to different stress conditions to
induce drug degradation. These sample solutions showed stability
against thermal and basic degradation conditions without formation
of degradation product peaks or reduction in the BSF content (Fig. 3A
and E). There was a reduction in the content of BSF under photo-
degradation, acid and oxidative conditions, but no additional peak
majority of degradation products was formed (Fig. 3B–D and F).
The chromatographic peak purity tool, applied to BSF peaks, demon-
strated that they remained pure in all cases, conﬁrming the absence
of other substance coeluting at the same retention time.
Bioassay method – To demonstrate the speciﬁcity, a placebo
solution was evaluated and showed no zones of inhibition when
assessed against a freshly prepared solution of BSF. A sample
solution was subjected to forced photolytic degradation (UVA) and
analyzed. The results showed a degradation of about 19% when the
sample solution was exposed to UV radiation for 120 min, similar
to those found by the HPLC method (22%). It was observed that the
degradation product formed did not interfere with the determina-
tion of the microbiological method for BSF.
The method showed speciﬁcity, because the excipients from
the formulation and the possible degradation product formed did
not interfere with the determination of BSF.
3.3.2. Linearity
HPLC method – The method was linear (r¼0.9998) at the drug
concentration range of 20–80 mg mL1. The representative linear
equation was y¼34.766xþ4.4175, where x is the concentration
and y is the area. According to ANOVA there is a linear regression
(po0.05) and there is no deviation from linearity (p40.05).
Student's t-test was performed to verify the signiﬁcance of the
experimental intercept in the linear regression equation. Accord-
ing to the results, there were no signiﬁcant differences from the
theoretical zero value for p40.05.
Bioassay method – The calculation procedure usually assumes a
direct relationship between the observed zone diameter and the
logarithm of the applied dose. The corresponding mean zone
diameters for reference solutions were 17.51 mm (RSD¼0.97)
for the lower dose (0.5 mg mL1), 21.33 mm (RSD¼0.88) for the
Fig. 2. Photos of inhibition zones obtained by microbiological method for determination of besiﬂoxacin (front and back of the card).
Table 1
Parameters tested during the development of microbiological assay for BSF ophthalmic
suspension determining.
Parameter Condition
Culture media Grove–Randall number 1
Grove–Randall number 11
Microorganisms Kochuria rhizophila ATCC 9341
Staphylococcus aureus ATCC 6538P
Staphylococcus epidermidis ATCC 12228
Diluent solution Water
Phosphate buffer pH 6.0
Phosphate buffer pH 7.0
Standard curve (mg mL1) 0.5; 1.0; 2.0
0.5; 1.5; 4.5
Inoculum (%) 1
2
Table 2
Final condition parameters established for microbiological assay of BSF.
Parameter Condition
Standard curve (mg mL1) 0.5, 1.0 and 2.0
Diluent solution Water
Microorganism Staphylococcus epidermidis ATCC 12228
Inoculum (%) 2.0
Incubation temperature (1C) 3572
Incubation time (h) 18
Culture media Grove–Randall number 11
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medium dose (1.0 mg mL1), and 24.30 mm (RSD¼0.55) for the
higher dose (2.0 mg mL1). The calibration curves found for BSF
were constructed by plotting the log concentration (mg mL1)
versus the zone diameter (mm) and showed good linearity in
the concentration range of 0.5 and 2.0 mg mL1. The representative
linear equation was y¼11.278xþ9.7687, where x is the log con-
centration and y is the zone diameter. The correlation coefﬁcient
(r¼0.9974) found was considered signiﬁcant for the method
(Fig. 4).
According to the Brazilian (2010) and European Pharmacopoeia
(2005), if a parallel-line model is chosen, the two log dose–
response lines of the preparation to be examined as well as the
reference preparation must be parallel and they must be linear
Fig. 3. Representative HPLC chromatograms obtained from the sample solution of besiﬂoxacin submitted to forced degradation: (A) 60 1C during 24 h; (B) UVC light for 1 h;
(C) UVA light for 1 h; (D) 1.0 M HCl for 1 h; (E) 1.0 M NaOH for 1 h; (F) 30% H2O2 for 1 h.
Fig. 4. BSF calibration curve obtained by the microbiological cylinder-plate assay.
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over the range of doses used in calculation. These conditions were
veriﬁed by a validity test for a given probability, usually p¼0.05.
The assays were validated by analysis of variance, as described in
these ofﬁcial guidelines. There was no deviation from parallelism
and linearity in the results presented here (p40.05).
3.3.3. Precision and accuracy
HPLC method – The precision of the method was determined
by repeatability (intra-day) and intermediate precision (inter-day)
and it was expressed as RSD (%). The low values of relative
standard deviations (RSD) for repeatability (0.74%, 1.73% and
0.88%) and intermediate precision (1.41%) showed adequate pre-
cision of the analytical method.
The accuracy was evaluated by simultaneously determining the
analyte in solutions prepared using the standard addition method.
The mean results were found to be 101.0%, indicating satisfactory
accuracy.
Bioassay method – The microbiological assay also demonstrated
precision and accuracy. The precision of the assay was determined
by repeatability (intra-assay) and intermediate precision (inter-
assay) in which values are expressed as relative standard deviation
(RSD) of the series of measurements performed on the same day
and on alternate days. Repeatability was demonstrated by the
low RSD found in the samples on the same day (0.53 to 1.15).
The intermediate precision was determined by analyzing samples
on three different days, where an RSD of 0.84% was obtained
(Table 3).
Accuracy was evaluated by simultaneously determining the
analyte in prepared solutions using the standard addition method.
Accuracy expresses the agreement between the accepted value and
the value found [15]. The mean values were found to be 101.4%.
3.3.4. Robustness
HPLC method – The method robustness was investigated
through little changes in the pH of the aqueous phase, percentage
of acetonitrile, ﬂow and percentage of triethylamine in order to
verify the inﬂuence of these modiﬁcations in the chromatographic
parameters (system suitability), such as area, theoretical plates,
retention time and retention factor.
No signiﬁcant changes were found in the chromatographic
pattern when the modiﬁcations were made, under experimental
conditions, thus the method was shown to be robust.
Bioassay method – To evaluate the robustness of the method the
concentration of the inoculated medium in the determination of
BSF (1.8 and 2.2%) varied. The values found in determining BSF
parameter related to robustness by modifying the concentration
of inoculum (103.9%) were very close to those obtained during
the validation tests (104.7%), demonstrating the robustness of the
method.
3.4. Photodegradation kinetics
Considering preliminary stability and photoreactivity studies,
the degradation kinetics of BSF under a UVA light condition
was performed (because it is an ophthalmic suspension without
restriction to daytime use).
All results obtained by microbiological assay were monitored
by previously validated HPLC. The effect of light exposure on the
residual BSF RS and on the pharmaceutical formulation/ocular
suspension is shown in Tables 4 and 5, respectively.
The reaction order for the degradation kinetics of BSF was
determined representing the residual drug concentration versus
time (zero order reaction), log concentration versus time (ﬁrst
order reaction), and the inverse of a function of concentration
versus time (second order). The linear regression coefﬁcients (r)
were obtained, and the coefﬁcient closer to unity indicates the
order of reaction. BSF RS was found to follow a second-order
reaction (A) while the ophthalmic suspension (B) followed a ﬁrst-
order reaction (Fig. 5).
With this information, through mathematical calculations, the
ﬁrst reaction rate constant (k) and lifetime (t90%) were determined.
For the BSF ophthalmic suspension (ﬁrst-order reaction) the
constant reaction corresponds to 0.0962 h1. In other words, it
deteriorates at a rate of approximately 9.62% per hour. For BSF RS
which follows a second-order reaction, the reaction constant was
0.0025 h1.
The lifetime (t90%) for BSF RS showed a value of 0.00499 min
or 0.299 s, while for the ophthalmic suspension the value was
1.095 h.
3.5. Cytotoxicity assay
A cytotoxicity assay with mononuclear cells was performed to
evaluate the effect of the degraded structures in relation to the
intact molecule, to foresee possible undesirable effects resulting
Table 3
Intra-assay and inter-assay precision data for the BSF bioassay in the pharmaceu-
tical formulation.
Sample Day Potency founda (%) RSD (%)
1 104.34
2 1 106.67 1.15
3 104.92
4 104.78
5 2 104.98 0.53
6 103.93
7 103.81
8 3 105.14 0.69
9 103.98
Inter-assay 104.73 0.84
a Mean of six determinations.
Table 4
BSF RS levels obtained after exposure to UVA light evaluated by HPLC and
microbiological method.
Time (min) BSF RS (%)
Microbiological assay* HPLC
0 100.0 100.0
15 99.3 99.5
30 96.9 95.0
60 80.2 87.0
90 76.6 77.0
120 71.6 68.0
150 68.8 63.0
n Mean of six replicates.
Table 5
BSF levels obtained in ophthalmic suspension after exposure to UVA light evaluated
by HPLC and microbiological method.
Time (min) BSF ophthalmic suspension (%)
Microbiological assaya HPLC
0 100.0 100.0
60 91.5 91.0
120 81.4 78.0
180 74.7 66.0
240 69.1 60.0
300 60.7 53.0
a Mean of three determinations.
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from unstable samples. Non-signiﬁcant differences (p 4 0.05)
were obtained, indicating that the degraded samples and intact
molecule did not show an increase in cytotoxicity after exposure to
the assayed cells for 5 h (Fig. 6).
3.6. Comparison of the methods
The results obtained with the cylinder plate assay were
comparable with those obtained by HPLC. For the microbiological
assay method, the mean potency found (RSD%) was 104.67%
70.85% and for the HPLC method, 102.83%71.29%. These results
were statistically analyzed using Student's t test and indicated
that there was no signiﬁcant difference between the methods
at α¼0.05 (tcalculated 1.46ottheoretical 2.12).
4. Conclusions
An HPLC method was developed and validated for quantitative
determination of BSF in ophthalmic suspension. Validation experi-
ments provide a proof that the HPLC method is speciﬁc, linear
in the proposed working range, as well as accurate, precise and
robust.
The proposed microbiological cylinder plate assay for determi-
nation of BSF in ophthalmic suspension is linear, precise, accurate,
speciﬁc and robust. Moreover, there is no statistical difference
between the microbiological assay and the HPLC method for drug
quantiﬁcation; therefore, these can be interchangeable. The vali-
dation proved that the microbiological assay is an excellent
alternative method for analyzing the pharmaceutical dosage form
in the BSF ophthalmic suspension, being a useful tool to supple-
ment or replace physico-chemical methods in quality control.
The degradation of BSF RS and the ophthalmic suspension
during the photochemical process are found to follow second-
order and ﬁrst-order reaction kinetics, respectively. The kinetic
parameters of the degradation rate constant, and t90% could be
predicted.
The cytotoxicity test showed that at all concentrations tested
(10–200 μg mL1), regardless of whether there is degradation, BSF
did not alter the cell membrane and, thus, it is considered non-
toxic to human mononuclear cells under the experimental condi-
tions tested.
These studies proved to be useful tools to control the quality of
the BSF ophthalmic suspension, encouraging its use in routine
analysis.
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Fig. 5. Second-order plots for the degradation of BSF RS (A) under UVA light and
ﬁrst-order plots of ophthalmic suspension (B) by microbiological assay.
Fig. 6. Results of lactate dehydrogenase (LDH) assay for cellular viability. Values of
100% indicate total cellular viability (control data). Triton X (1%) exhibited cellular
death, being used as a positive control. n indicates signiﬁcant differences between
means (po0.05).
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